Mouse 16S microbiome sequencing to investigate the use of NET-inhibitory peptides for the treatment of and prophylaxis against inflammatory disorders

Sepsis or bloodstream infection causes significant morbidity and mortality worldwide. Empiric antibiotics with a rapid transition to microbe-specific antibiotics remain the mainstay of sepsis treatment. When early signs of sepsis are recognized, antibiotic treatment can prevent death and disease sequelae. However, empiric use of antibiotics facilitates antibiotic resistance which has become a global problem. In this study, we investigated a novel therapeutic agent called neonatal NET-Inhibitory Factor (nNIF) in a mouse model of experimental sepsis.